Technavio Announces the Publication of its Research Report
Global Pharmaceutical Contract Manufacturing Market 2016-2020
Technavio recognizes the following companies as the key players in the global pharmaceutical contract manufacturing market: Catalent, Lonza, and Pfizer CentreOne.
Other prominent vendors in the market are: Abbott, Aenova, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, BERLIN-CHEMIE, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, Daiichi Sankyo, Dr. Reddy's Laboratories, Eli Lilly, Emcure Pharmaceuticals, Eurofarma Laboratories, Fareva, Gedeon Richter, Gilead Sciences, GlaxoSmithKline (GSK),Hospira, Impax Laboratories, Intas Pharmaceuticals, Janssen Pharmaceuticals, Lupin, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Natco Pharma, Nexus Pharmaceuticals, Novo Nordisk, Orchid Chemicals & Pharmaceuticals, Par Pharmaceutical, Parenteral Drugs India, Patheon, Piramal, Roche Holding, Sanofi, Synthon, Teva Pharmaceuticals, Valeant Pharmaceuticals, Zentiva, Zhejiang Huahai Pharmaceutical, and Zydus Cadila.
Commenting on the report, an analyst from Technavio’s team said: One of latest trends in the market is consolidation through vertical integration, alliances, and acquisitions. The major pharmaceutical companies have decreased their operations and R&D budgets, which has led to an increase in demand for outsourced services. Moreover, companies have consolidated their infrastructure in response to a sharp global economic downturn, poor revenue growth prospects, and expensive and inefficient operations. Strategic partnerships between pharmaceutical companies and CMOs have led to the reduction of government spending on manufacturing. The past few years have brought major changes to the pharmaceutical outsourcing services. As more in-house positions have been removed, pharmaceutical vendors are looking for strategic partnerships and 'one-stop' solutions.”
Technavio recognizes the following companies as the key players in the global pharmaceutical contract manufacturing market: Catalent, Lonza, and Pfizer CentreOne.
Other prominent vendors in the market are: Abbott, Aenova, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, BERLIN-CHEMIE, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, Daiichi Sankyo, Dr. Reddy's Laboratories, Eli Lilly, Emcure Pharmaceuticals, Eurofarma Laboratories, Fareva, Gedeon Richter, Gilead Sciences, GlaxoSmithKline (GSK),Hospira, Impax Laboratories, Intas Pharmaceuticals, Janssen Pharmaceuticals, Lupin, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Natco Pharma, Nexus Pharmaceuticals, Novo Nordisk, Orchid Chemicals & Pharmaceuticals, Par Pharmaceutical, Parenteral Drugs India, Patheon, Piramal, Roche Holding, Sanofi, Synthon, Teva Pharmaceuticals, Valeant Pharmaceuticals, Zentiva, Zhejiang Huahai Pharmaceutical, and Zydus Cadila.
Commenting on the report, an analyst from Technavio’s team said: One of latest trends in the market is consolidation through vertical integration, alliances, and acquisitions. The major pharmaceutical companies have decreased their operations and R&D budgets, which has led to an increase in demand for outsourced services. Moreover, companies have consolidated their infrastructure in response to a sharp global economic downturn, poor revenue growth prospects, and expensive and inefficient operations. Strategic partnerships between pharmaceutical companies and CMOs have led to the reduction of government spending on manufacturing. The past few years have brought major changes to the pharmaceutical outsourcing services. As more in-house positions have been removed, pharmaceutical vendors are looking for strategic partnerships and 'one-stop' solutions.”
According to the report, one of the primary drivers in the
market is high number of US FDA-approved manufacturing facilities in emerging
countries. While selecting a partner for outsourcing, pharma companies look for
the US FDA-approved plants along with skilled workforce and low operating
costs. India, with more than 100 US FDA approved manufacturing facilities, is
one of the most preferred locations for outsourcing manufacturing services.
According to the research studies published in 2015, Indian suppliers accounted
for around 25%-30% of the total drug master files (DMFs) filed with the US FDA.
In addition, the implementation of the WTO TRIPS-mandated product patents
(January 2005) has led to a rise in outsourcing in the developed markets.
Further, the report states that one major challenge in the market is lack of information integration. One of the greatest challenges faced by most vendors in the pharmaceutical contract manufacturing market is the lack of transparency and information integration in the whole supply chain process. Few medicines, especially vaccines and specialty injections, need fast delivery to ensure their utility. If companies are equipped with a centralized system, they will be able to observe changes in inventory and can order shipments as per requirements. Distribution vehicles or shipments can be redirected to obtain drugs in the required areas. With the right integration of available data from all the stages within the supply chain, companies can keep track of orders and delivery rates. This can effectively cure the delays and disruptions in the pharmaceutical supply chain, making the entire value chain effectively responsive to the unmet medical needs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Get discount: https://marketreportscenter.com/request-discount/455982
Further, the report states that one major challenge in the market is lack of information integration. One of the greatest challenges faced by most vendors in the pharmaceutical contract manufacturing market is the lack of transparency and information integration in the whole supply chain process. Few medicines, especially vaccines and specialty injections, need fast delivery to ensure their utility. If companies are equipped with a centralized system, they will be able to observe changes in inventory and can order shipments as per requirements. Distribution vehicles or shipments can be redirected to obtain drugs in the required areas. With the right integration of available data from all the stages within the supply chain, companies can keep track of orders and delivery rates. This can effectively cure the delays and disruptions in the pharmaceutical supply chain, making the entire value chain effectively responsive to the unmet medical needs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Get discount: https://marketreportscenter.com/request-discount/455982
About Pharmaceutical Contract
Manufacturing
Contract manufacturing involves outsourcing manufacturing products to organizations, which helps the organizations offer the same services at a relatively lower cost. Typically, in the pharmaceutical and biotechnology sectors, the sourcing companies seek contract manufacturing services to restructure their resource deployment toward high skill areas such as R&D and marketing. Contract manufacturing has potential growth opportunities in emerging countries such as India and China.
Technavio’s analysts forecast the global pharmaceutical contract manufacturing market to grow at a CAGR of 6.91% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global pharmaceutical contract manufacturing market for 2016-2020. To calculate the market size, the report considers the revenue generated from various pharmaceutical drug manufacturing outsourcing activities.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Pharmaceutical Contract Manufacturing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Catalent
• Lonza
• Pfizer CentreOne
Other prominent vendors
• Abbott
• Aenova
• Amgen
• Apotex
• Aspen
• AstraZeneca
• Aurobindo Pharma
• Baxter
• BERLIN-CHEMIE
• Biocon
• Biogen
• Boehringer Ingelheim
• Celltrion
• Cipla
• Coherus Biosciences
• Daiichi Sankyo
• Dr. Reddy's Laboratories
• Eli Lilly
• Emcure Pharmaceuticals
• Eurofarma Laboratories
• Fareva
• Gedeon Richter
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Hospira
• Impax Laboratories
• Intas Pharmaceuticals
• Janssen Pharmaceuticals
• Lupin
• Merck
• Mitsubishi Tanabe Pharma
• Momenta Pharmaceuticals
• Natco Pharma
• Nexus Pharmaceuticals
• Novo Nordisk
• Orchid Chemicals & Pharmaceuticals
• Par Pharmaceutical
• Parenteral Drugs India
• Patheon
• Piramal
• Roche Holding
• Sanofi
• Synthon
• Teva Pharmaceuticals
• Valeant Pharmaceuticals
• Zentiva
• Zhejiang Huahai Pharmaceutical
• Zydus Cadila
Market driver
• High number of US FDA-approved manufacturing facilities in emerging countries.
• For a full, detailed list, view our report
Market challenge
• Capacity utilization issues and lack of information integration.
• For a full, detailed list, view our report
Market trend
• Huge demand for next-generation biologics.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Contract manufacturing involves outsourcing manufacturing products to organizations, which helps the organizations offer the same services at a relatively lower cost. Typically, in the pharmaceutical and biotechnology sectors, the sourcing companies seek contract manufacturing services to restructure their resource deployment toward high skill areas such as R&D and marketing. Contract manufacturing has potential growth opportunities in emerging countries such as India and China.
Technavio’s analysts forecast the global pharmaceutical contract manufacturing market to grow at a CAGR of 6.91% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global pharmaceutical contract manufacturing market for 2016-2020. To calculate the market size, the report considers the revenue generated from various pharmaceutical drug manufacturing outsourcing activities.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Pharmaceutical Contract Manufacturing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Catalent
• Lonza
• Pfizer CentreOne
Other prominent vendors
• Abbott
• Aenova
• Amgen
• Apotex
• Aspen
• AstraZeneca
• Aurobindo Pharma
• Baxter
• BERLIN-CHEMIE
• Biocon
• Biogen
• Boehringer Ingelheim
• Celltrion
• Cipla
• Coherus Biosciences
• Daiichi Sankyo
• Dr. Reddy's Laboratories
• Eli Lilly
• Emcure Pharmaceuticals
• Eurofarma Laboratories
• Fareva
• Gedeon Richter
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Hospira
• Impax Laboratories
• Intas Pharmaceuticals
• Janssen Pharmaceuticals
• Lupin
• Merck
• Mitsubishi Tanabe Pharma
• Momenta Pharmaceuticals
• Natco Pharma
• Nexus Pharmaceuticals
• Novo Nordisk
• Orchid Chemicals & Pharmaceuticals
• Par Pharmaceutical
• Parenteral Drugs India
• Patheon
• Piramal
• Roche Holding
• Sanofi
• Synthon
• Teva Pharmaceuticals
• Valeant Pharmaceuticals
• Zentiva
• Zhejiang Huahai Pharmaceutical
• Zydus Cadila
Market driver
• High number of US FDA-approved manufacturing facilities in emerging countries.
• For a full, detailed list, view our report
Market challenge
• Capacity utilization issues and lack of information integration.
• For a full, detailed list, view our report
Market trend
• Huge demand for next-generation biologics.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Table of content: https://marketreportscenter.com/reports/455982/global-pharmaceutical-contract-manufacturing-market-2016-2020#toc
About Us:
Market Reports
Center is an e-commerce platform obliging the needs of knowledge workers,
experts, professionals who are subject to market research information for their
work, or to make strategic business decisions. Market Reports Center’s team
consistently works to update and extend our existing repository of market
research reports by partnering with new publishers and adding their studies to
our website.
Contact us for more details:
Sam Collins
Market Reports
Center
Phone No: 1-646-883-3044 (US)
No comments:
Post a Comment